USFDA20 Jul 2026, 04:15 pm

Wanbury Ltd: USFDA inspects Tanuku facility, issues Form 483 with 6 observations

AI Summary

Wanbury Ltd announced that the United States Food and Drug Administration (USFDA) conducted a routine Current Good Manufacturing Practices (cGMP) inspection at its facility in Tanuku, West Godavari District, Andhra Pradesh, from July 13 to July 17, 2026. Following the inspection, the USFDA issued a Form 483 with six observations. The company stated it will respond to these observations within the stipulated timeframe and will provide further updates as necessary.

Key Highlights

USFDA conducted a cGMP inspection at Wanbury's Tanuku facility.
Inspection took place between July 13-17, 2026.
USFDA issued a Form 483 with six observations.
Company will respond to observations within the stipulated time.

View BSE Filing

WANBURY

Pharmaceuticals

WANBURY LTD.

Price Impact